||Recombinant Human TNFSF14 (Accession # O43557), fused with , was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
||Measured in a cytotoxicity assay using HT-29 human colon adenocarcinoma cells Yu, K.Y. et al. (1999) J. Biol. Chem. 274:13733; Harrop, J.A. et al. (1998) J. Biol. Chem. 273:27548; Zhai, Y. et al. (1998) J. Clin. Invest. 102:1142.rhLIGHT at 10 ng/mL causes a 2-4.5 fold inhibition of HT29 proliferation, in the presence of 10 U/mL (1 ng/mL) rhIFN-gamma.Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323.The ED50 for this effect is typically 1-4 ng/mL.
||Recombinant Human TNFSF14 has a calculated MW of 20.9 kDa. In SDS-PAGE migrates as 25 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).